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Abstract 
Introduction: In South Africa, up to 30% of pregnant women are human 
immunodeficiency virus (HIV) positive and morbidity and mortality is high 
in this group. HIV positive men and women may have multiple 
cardiovascular comorbidities, which include systolic dysfunction that may 
progress to heart failure secondary to dilated cardiomyopathy. However the 
concurrent effect of pregnancy and HIV infection on haemodynamics has not 
been extensively researched. The aims of this study were to quantify 
haemodynamics using transthoracic echocardiography (TTE) in term 
pregnant women with HIV on antiretroviral (ARV) treatment and compare 
the data with term healthy women in the same population.   
Method: After ethics approval and written consent, 30 consecutive term HIV 
positive women and 40 healthy term pregnant women were recruited. HIV 
positive women had a CD4 count greater than 200 and were either on Highly 
Active Anti-Retroviral Therapy (HAART) or single drug management.  
Results: Haemodynamic assessment was possible in all patients and women 
in the two groups were similar in age, and body mass index. Mean CD4 count 
was 452 ± 187.8 and duration of therapy was 15.9 ± 22.4 months. Compared 
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with healthy pregnant women, women with HIV have systolic changes 
exhibited by reductions in left ventricle (LV) septal and right ventricle (RV) 
systolic myocardial velocities as well as increased LV end-diastolic (ED) areas 
and diastolic changes of increased RV isovolumetric (IV) relaxation and 
reduced RV e′ diastolic myocardial velocities. These changes occur in the 
presence of a reduced LV mass. Pericardial effusions occurred more 
frequently and are of a larger size in women with HIV.  
These findings suggest subclinical impairment of systolic function in the LV 
as well as subclinical impairment of both systolic and diastolic function in the 
RV.  
Discussion: Transthoracic echocardiography can quantify cardiac function in 
healthy pregnant women and in pregnant women with HIV and is acceptable 
to the patients. HIV positive pregnant women at term on anti-retroviral 
therapy have hearts that have subclinical systolic dysfunction in the presence 
of decreased LV mass and increased end-diastolic areas. This may represent a 
failure to compensate for the increased haemodynamic demands of 
pregnancy and may be as a result of the direct effects of HIV itself or due to 
anti-retroviral drugs. 
•  Preliminary results of this work were presented as an oral presentation 
and a published abstract at The Obstetric Anaesthetists Association 
meeting Dublin, United Kingdom May 2014: Dennis AT, Dyer RA, 
Gibbs M, Nel L, Castro JM, Swanevelder JL. Cardiac function and 
structure using transthoracic echocardiography in term HIV positive 
women. International Journal of Obstetric Anesthesia 2014; 23(S1): S7  
o Best trainee presentation at The Obstetric Anaesthetists 
Association meeting Dublin, United Kingdom May 2014 
 
Subsequent to finalising the transcript of this paper for the International 
Journal of Obstetric Anesthesia, it was decided to include this work and 
publish it in Anaesthesia as part of the larger ‘Transthoracic 
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Echocardiography in Pregnant Women’ study, HREC 442/2013, hence some 
of the similarities highlighted in the attached Turnitin report.  
 
Dennis, A. T., Dyer, R. A., Gibbs, M., Nel, L., Castro, J. M. and Swanevelder, 
J. L. (2015), Transthoracic echocardiographic assessment of haemodynamics 
















Quantification of cardiac structure and function using transthoracic 
echocardiography in term women with HIV 	
An observational study of healthy term pregnant women and pregnant 
women with human immunodeficiency virus.	
	
	
Matthew Gibbs, Anaesthesia Registrar, Department of Anaesthesia, 





The identification of cardiac disease in pregnancy is made difficult by the 
physiological changes of pregnancy, which result in increasing dyspnoea and 
diagnostic challenges associated with the gravid uterus.  Recent 
developments in transthoracic echocardiography (TTE), a noninvasive 
technique involving the placement of an external probe on the woman’s chest 
wall, have led to elucidation of cardiac physiology and pathophysiology of 
pregnancy.1 TTE not only enables better definition of cardiac dysfunction, but 
also contributes to point of care management.2 TTE has been shown to be 
acceptable and applicable in pregnant women with no known side effects.	
	
Human immunodeficiency virus (HIV) positive women have many 
cardiovascular comorbidities, which include an as yet undefined incidence of 
systolic dysfunction, which may progress to heart failure due to dilated 
cardiomyopathy. Research in Rwanda has shown that HIV-associated dilated 
cardiomyopathy may occur in up to 17% of untreated HIV positive patients.3 
In another prospective cohort trial, the incidence of systolic dysfunction was 
up to 34% and diastolic dysfunction of 48% in asymptomatic HIV positive 
patients on HAART.4 The effect of pregnancy and HIV infection on 
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haemodynamics has not been extensively researched. A recent limited study 
in Uganda suggests that HIV infection in patients on HAART is not 
necessarily a risk factor for the echocardiographic signs of cardiomyopathy or 
pulmonary hypertension.5 In South Africa, up to 30% of parturients 
presenting for delivery at State Hospitals are HIV positive.6  TTE could help 
identify cardiac dysfunction, guide treatment, and reduce risk in these 
patients. As a convenience sample, thirty patients will be studied, due to the 
lack of studies performed in this population. 	
A group of forty gestationally matched healthy pregnant women will be 
studied as a basis for comparison.	
	
Overall, the use of TTE in the patients recruited to this study can only be of 
benefit, both as an aid to diagnosis of cardiac pathology in the individual 




That term pregnant women with HIV infection have reduced systolic function 




To determine the differences, if any, between the haemodynamics, cardiac 
function and structure of term HIV pregnant women and healthy term 





This study will be conducted with Institutional Ethics Committee approval. 
Participant recruitment will take place on the day of the study.	
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Experimental design and location	
	
This will be a prospective observational study performed at Mowbray 




The study will involve two groups of pregnant women: 	
1. Healthy term women (40 women)	




Healthy pregnant women (term and preterm)	
	
Healthy pregnant women will be gestationally matched with women with 
HIV. Healthy pregnant women are defined as American Society of 
Anesthesiologists (ASA) Classification I or II, with no significant medical or 
surgical illness, singleton pregnancy, with no uterine abnormalities and 
normally defined placentation. They will not be receiving any vasoactive 
medication including salbutamol or thyroid replacement hormones. Healthy 
pregnant women will be recruited from a variety of settings throughout the 
hospital.	
	
Term women with HIV 	
	
Thirty HIV positive women who are ≥ 37 weeks gestation will be recruited. 
The most recent CD4 count must be greater than 200, and all patients must be 
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Exclusion criteria include current administration of vasoactive drugs 
including salbutamol and thyroxine, pre-existing or gestational diabetes, 
known cardiac disease including pre-existing or gestational hypertension, 
multiple pregnancy, a known uterine abnormality or abnormal placentation, 
any woman in labour, inability to consent to the study.	
	
Women with HIV 	
	





All participants will rest in the left lateral flat position for a minimum of five 
minutes before the measurements. Baseline systolic and diastolic blood 
pressure will be obtained non-invasively using a calibrated 
sphygmomanometer on the left arm recording the diastolic value as Korotkoff 
V according to the American Heart Association.7 An electrocardiograph 
(ECG) will be attached to each woman. All TTE studies will be performed by 
either the investigator AD or LN, according to published guidelines by the 
American Society of Echocardiography (ASE).8–12 The parasternal long axis 
(PLAX), parasternal short axis (PSAX), apical 2-, 4- and 5- chamber (A2C, 
A4C, A5C) views will be obtained, including 2-dimensional imaging and 
continuous, pulse wave, colour flow and tissue Doppler will be performed. 
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Images will be converted to digital images and communications in medicine 
(DICOM) format and analysed off-line using ProSolv® software. Two 
investigators will independently review and measure the stored images in 
random order (Professor AT Dennis and Dr. Julian Castro). Each investigator 
will record an average of three consecutive beats. Inter- and intraobserver 
variability will be calculated.	
	
Participant baseline demographic, obstetric, biochemical and urinary data 
will be collected. Haemodynamic and systolic cardiac data as well as diastolic 
and structural cardiac data will be obtained.	
	
Management of abnormalities findings	
	
Abnormalities detected by TTE will be immediately notified to the treating 
clinician.	
	
Rationale for the sample size 	
	
The sample size of 40 pregnant women in the term healthy groups is based on 
data from previous published work.13	
	
The sample size of 30 women with HIV and term pregnancy is a convenience 
sample. This will enable the range of haemodynamics in this group to be 
determined thereby facilitating the design and estimation of the sample size 
for a larger study.	
	
Statistical and mathematical methods 	
	
Demographic and obstetric data will be displayed as mean and standard 
deviation, median with interquartile ranges, or number and percentage as 
appropriate. Analysis of recorded TTE variables and heart rate and blood 
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pressure will be made using analysis of variance (ANOVA) and a General 
Linear Model with significant p value defined as < 0.05 after performing F 
tests on the collected data. Pearson’s correlation will be used to assess the 
strength of the linear relationship between variables. All the haemodynamic 
measurements from one participant will be assumed to be a family of 
measurements, therefore a Ryan-Holm stepdown Bonferroni procedure will 
be applied to the outcomes of the ANOVA in order to reduce the risk of a 
Type 1 error.14–16 The null hypothesis will be rejected if critical p < 0.05 for 
each of the variables. 	
	
Ethical considerations and consent	
	
Echocardiography will be performed at the time of recruitment. Most patients 
will be recruited from the Antenatal clinic at Mowbray Maternity Hospital, 
with additional recruitment taking place in MK ward, Groote Schuur 
Hospital. Hospital-wide awareness of the study and immediate notification of 
the investigators will be an important factor in the success of the study. 
Patient demographic, haemodynamic and echocardiographic data will be 
examined without any related identifiers. Prospective written informed 
consent will be obtained in patients recruited to the study. No treatment delay 
or affect on patient flow is expected. All information regarding the study will 





Participant recruitment and scanning will take place over an intensive two-
week period. Two investigators including the scanning investigator will be 
exclusively available for most of this time period to recruit and scan eligible 
pregnant women. Each TTE scan will take approximately 15-20 minutes to 
perform with all measurements being performed offline. It is estimated that 
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Anticipated outcomes of this study	
	
1. Increased understanding of the range of haemodynamics and cardiac 
structure in women who are pregnant at term and HIV positive	
2. Increased understanding of the haemodynamics and cardiac structure 
in healthy pregnant women 	




It is anticipated that this work will be published in peer- reviewed journals 
and that the de-identified TTE data obtained in this study will be used for 
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A search of the Pubmed, SCOPUS and Google Scholar databases was 
performed, using the keywords: “HIV”, “cardiomyopathy”, 
“echocardiography”, and “pregnancy”. Pertinent articles were reviewed and 
further references were extracted from the relevant papers.  
Introduction 
Human Immunodeficiency Virus (HIV) infection has reached pandemic 
proportions with an estimated global population of 35 million infected 
people.1 In Sub-Saharan Africa, the prevalence is 4.7% as compared to a 
worldwide prevalence of 0.8%. South Africa is disproportionately affected 
with a prevalence of 10%, approaching thirty percent in pregnant women, 
significantly effecting morbidity and mortality. 53% of maternal deaths are 
due to non-pregnancy related infections and, of those, ninety percent are HIV 
positive.2 
 
Cardiovascular effects of pregnancy 
 
Pregnancy causes a swathe of changes in a woman’s body, the cardiovascular 
system being notably affected by momentous hormonal fluctuations. Such 
changes include an increase in blood volume of 35%, plasma volume by 45%, 
cardiac output by 40% and falls in systolic and diastolic blood pressure as 
well as peripheral resistance and pulmonary resistance.3 Hormonal changes 
are also encountered including elevated oestrogen and human placental 
lactogen levels. As cardiac output increases over the course of pregnancy, it is 




Transthoracic echocardiography is a non-invasive measure of 
haemodynamics and cardiac structures using ultrasound. Despite the obvious 
difficulty of obtaining images with a gravid uterus, particularly the subcostal 
four-chamber view, pregnancy has certain advantages as regards to finding 
ideal acoustic windows for echocardiography. As partial left tilt is necessary 
to reduce the aortocaval compression induced by the gravid uterus, this, 
along with an elevated diaphragm, results in anterior and left displacement of 
the heart, bringing structures closer to the transducer.4 Because of their 
exposure to ultrasound early in pregnancy, and the low risk involved, 
echocardiography is well accepted by pregnant patients.5 Echocardiography 
has the advantage of not only quantifying cardiac function but also 
visualizing cardiac structures in 2- and 3-D, and, as it can be performed at the 
bedside, can benefit point-of-care management.6 
 
Various longitudinal studies on the haemodynamics of pregnancy have been 
performed using echocardiography in the healthy pregnant population, 
validating this technique in this population. Desai and Moodley in 2004 
performed 160 echocardiographic studies on 35 healthy pregnant patients 
from early second trimester until term and until 6-12 weeks after delivery.7 
They showed a gradual increase in cardiac output over second trimester with 
peak values being reached in early to mid third trimester. This cardiac output 
was maintained until term and left ventricular function was not affected. 
Cardiac output increased by 46-51% from base values, contributed to by an 
increase in stroke volume of 24% and heart rate of 15%. Structural changes 
included an increase in left atrial size and left atrial/aorta size ratio and 
increases in LV mass and LV mass index (compensating for Body Mass 
Index). Values returned to normal by 6-8 weeks post partum. 
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An earlier study using echocardiography but with only 18 patients was also 
performed in the USA.8 Studies were performed in the first trimester and then 
regularly until 6 to 12 weeks postpartum. The investigators found similar 
results, with an increase in stroke volume of 18% and heart rate 29%, with a 
concomitant increase in LV mass and wall thickness. Peak cardiac output was 
at 36-39 weeks.  
 
Simmons et al examined 44 normotensive women during the course of their 
pregnancy using echocardiography and found an increase in cardiac index of 
25% between the first and third trimesters.9 Due to a concern that a pregnancy 
induced rise in cardiac index could result in LV hypertrophy and a decrease 
in contractility, the investigators examined load independent variables of 
systolic function including end-systolic stress (ESS) and rate-corrected 
velocity of circumferential fiber shortening (VCFC). The LV wall thickened on 
average by eleven percent, resolving in the postpartum phase, and LV mass 
index increased from 66 to 76 g/m2, on average. Although there was a 
decrease in ESS and a small increase in VCFC, there was no significant change 
in the relationship between ESS and VCFC during the course of pregnancy. 
This demonstrated that women with a normal blood pressure during 
pregnancy did not have any changes in contractility. Left ventricular function 
also remained preserved, and demonstrated the ability of the heart of the 
normal pregnant woman to adequately compensate for the increased 
intravascular volume of pregnancy. 
 
These findings show significant cardiac changes during normal pregnancy 
with peak effects occurring at or near term. They also show how 
echocardiography can be used to investigate the haemodynamics of 
pregnancy in a repeatable fashion, to an international standard. 
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Transthoracic echocardiography in obstetric critical illness  
 
Echocardiography has also proved to be useful in the emergent setting in 
obstetrics. Papers by Dennis et al demonstrate the feasibility of transthoracic 
echocardiography as a point-of-care device to help illicit information that 
helps guide management of critically ill patients.4 Point-of-care 
echocardiography can be useful in divergent conditions, such as hypotension 
and maternal collapse,6 breathlessness10 and preeclampsia.11 
Echocardiography is able to provide information on regional wall motion 
abnormalities, the presence of shunting, global ventricular function, chamber 
size, the presence of emboli (whether amniotic, thrombotic or air) and 
pericardial effusions.  
The ROSE examination (Rapid Obstetric Screening Echocardiography) is a 
protocol developed by Dennis,4 which has the following elements: 
• It is acceptable and applicable 
• It is a bedside test performed in the left lateral position 
• It is a comfortable and concise examination, primarily focused on the 
parasternal short and long axis as well as the apical 4 chamber view 
• It is focused on the diagnosis and response to any therapy instituted – 
in particular, assessment of contractility and volume status 
• A rapid scan for any embolism present may be performed (e.g. 
air/amniotic fluid/thrombus) by imaging right heart function and 
relative size 
• The exam also allows fetal heart rate assessment to be made. 
A ROSE is indicated whenever obstetric critical illness is encountered: major 
obstetric haemorrhage, cardiac failure, sepsis, preeclampsia, aortic dissection, 
trauma and even in respiratory emergencies such as asthma. 
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HIV Molecular Biology 
 
Human Immunodeficiency Virus is a ribonucleic acid (RNA) retrovirus, 
identified in 1983, that produces deoxyribonucleic acid (DNA) from RNA via 
reverse transcriptase, a common target for drug therapy.12 Two other 
important targets for drug therapy include integrase, which is responsible for 
the integration of the HIV DNA produced into the cell DNA, and protease, 
which cleaves the protein precursors produced by the modified cell DNA into 
the final proteins required in the infectious viron. The virus also expresses 
three important proteins: GP120 (on the surface membrane), GP41 (through 
the cell membrane) and p24 (inside the body of the virus, on the 
nucleocapsid). Once inside the CD4+ cell, the GP120 and GP41 remain as 
GP160, which is used later for forming new viral membranes. The HI virus 
targets mainly CD4 positive T lymphocytes (recognized by the GP120 
molecule, and a co-receptor like CCR5 or CXCR4) and CD4+ cells of 
monocytes lineage, but can infect any CD4 expressing cell.13 Therefore, cells in 
the liver, lung and heart can all be affected. After replication of the viral DNA, 
protein synthesis and new viron formation, CD4 death results from cell lysis 
or by cell exhaustion from the excess protein production required. 
 
Cardiovascular effects of HIV 
 
Even in the pre-HAART era, it was clear that HIV infected men and non-
pregnant women had a high incidence of cardiovascular diseases. Cohen first 
linked HIV to a dilated cardiomyopathy in 1986, in a case series of three 
patients with AIDS.14 Other cardiac manifestations in HIV positive patients 
include systolic dysfunction, diastolic dysfunction, pericardial effusions, 
coronary artery disease, dilated cardiomyopathy or pulmonary hypertension. 
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Pathogenesis includes direct myocardial invasion by the HI virus, 
opportunistic infections, abnormalities of the autonomic nervous system, 
autoimmune disorders, endothelial dysfunction, HIV related malignancies 





HIV requires a CD4 receptor and a co-receptor (either CCR5 or CXCR4) to 
bind cell wall proteins thereby entering the cell. Because some cardiac 
myocytes lack a CD4 receptor, HIV cannot bind and enter these cells. 
However, HIV can enter and infect myocardial interstitial cells. The gp120 
subunit of the HIV envelope glycoprotein has been implicated in HIV-
associated cardiomyopathy. P38 mitogen-activated protein (MAP) kinase is 
part of a group of intracellular enzymes that phosphorylate proteins in 
response to inflammatory mediators (like cytokines) and stress (ischaemia). 
The HIV gp120 subunit has been associated with prolonged MAP kinase 
pathway activation that may lead to delayed negative inotropy, ischaemia 
and chronic heart failure as well as mitochondrial damage.13  
Myocarditis is also commonly found in HIV positive patients with 
cardiomyopathy. In one case series of patients with HIV and dilated 
cardiomyopathy who underwent endomyocardial biopsy, 63 out of 76 
patients had a histological diagnosis of myocarditis.16 Common causative 
organisms included Coxsackie virus B3, Epstein-Barr virus and Toxoplasma 
Gondii. Even in patients without diagnosed cardiomyopathy, myocarditis was 
diagnosed in 28% of patients at necropsy in a Brazilian case series.17 
HIV may also cause chronic immune activation via the production of 
interleukin-1 (IL1) and Tumour Necrosis Factor-alpha (TNF-alpha).18 
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Inducible nitrous oxide synthase (iNOS) levels are also higher in HIV 
associated cardiomyopathy when compared to idiopathic dilated 
cardiomyopathy (IDCM) and healthy controls.19 This again suggests a role for 
cytokine activation in the development of HIV-associated cardiomyopathy.  
 
Besides the effects of the virus itself, the treatment used may also cause 
cardiovascular complications. HAART can cause cardiac pathology via either 
direct toxic means or via changes to metabolism resulting in dyslipidaemia. 
Particular drug classes implicated are the Nucleoside Reverse Transcriptase 
Inhibitors (NRTIs) such as Zidovudine (AZT) and the Protease Inhibitors (PIs) 
like Ritonavir. The NRTIs were one of the first drugs to be used to treat HIV 
infection, and when initially administrated in high doses and as a single drug, 
it caused dilated cardiomyopathy and cardiac failure in a significant portion 
of patients.20 NRTIs prevent the reverse transcriptase process whereby the 
virus is incorporated into cell DNA. They also inhibit Pol-γ, an enzyme 
involved in the replication of mitochondrial DNA. This results in 
mitochondrial dysfunction and therefore problems may arise in cells that rely 
on mitochondria for energy production like cardiac myocytes.18 
 
Protease inhibitors, on the other hand, produce dyslipidaemia by a number of 
mechanisms. Although protease inhibitors are very specific in their effects on 
HIV protease, resulting in immature virions being released, they are similar in 
size and shape to cellular protease substrates. This results in inhibition of 
cellular enzymes involved in lipid metabolism and in the regulation of 
adipocytes. This, in turn, leads to metabolic dysfunction and 
lipodystrophy.21,22. They also inhibit GLUT-4 in adipocytes, resulting in 
defective glucose uptake, insulin resistance and type 2 diabetes.23 Accelerated 
atherosclerotic disease is also a concern.24 A 2002 study of 5672 HIV positive 
patients from the HOPS (HIV Outpatient Study) showed that the use of 
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protease inhibitors was strongly associated with the likelihood of having a 
myocardial infarction. Logistic regression models, controlling for factors such 
as diabetes and hypertension, still showed a strong association of myocardial 
infarction with the use of protease inhibitors.25 
 
Prevalence of HIV-associated cardiac dysfunction 
 
HIV associated cardiac dysfunction is more common than once thought. 
Clinical manifestations, including breathlessness and chest pain, are common, 
however it is dysfunction at the subclinical level that raises the need for 
increased vigilance. In a prospective cross sectional cohort study of HIV 
positive patients without symptoms of heart failure, Reinsch and colleagues 
found that 32% of patients had mild systolic dysfunction as indicated by LV 
ejection fraction of between 45% and 54%.26 Up to 48% had diastolic 
dysfunction as evidenced by impaired mitral annular plane excursion and 
38.7% of patients had an E/A ratio less than 1. This was in a first world 
environment in patients who were mostly on HAART with an average CD4 
count of 509/mm3. Investigating a cohort of treatment-naïve New York Heart 
Association (NYHA) Class 1 HIV positive patients with a CD4 greater than 
600, Barbaro et al showed that there was a mean reduction in ejection fraction 
by 19.7%, E/A ratio by 34.6% and an increase in isovolumetric relaxation time 
of 19.7% as compared with healthy controls, again implying subclinical 
systolic and diastolic dysfunction.27 
 
Twagirumukiza et al prospectively recruited 416 HIV-infected African 
patients who did not have documented cardiovascular disease. In a third 
world environment and an ARV-naïve population in Rwanda, they found 71 
patients (17.7%) had dilated cardiomyopathy, defined by LV ejection fraction 
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less than 45% and LV dilatation (LV end-diastolic volume index >80ml/m2.28 
These patients had a lower mean CD4 count and higher mean HIV-1 plasma 
viral load than patients without cardiomyopathy. Cardiomyopathy also 
correlated with duration of HIV infection, increased viral load, WHO clinical 
staging, low socio-economic status and low plasma selenium levels.  
 
This is in keeping with a study in Cameroon by Nzuobonatane and 
colleagues, who prospectively performed echocardiography on 75 patients 
referred for HIV testing.29 Of 54 HIV positive patients, with a mean CD4+ of 
119/mm3, 23.3% had a dilated cardiomyopathy, as defined by left ventricular 
fractional shortening <28% and left ventricular dilatation (LVEDD/BSA 
>3.2cm/m2). A dilated cardiomyopathy was far more likely to be present with 
a CD4 count less than 100/mm3: 31.58% (<100/mm3) vs. 6.06% (>100/mm3). 
The striking aspect of these two studies was that most patients were clinically 
free from specific signs and symptoms of cardiovascular disease and suggests 
that cardiac abnormalities in African HIV-positive patients can be difficult to 
discern clinically.  
 
 Olusegun-Joseph et al performed echocardiography on 100 HIV positive 
male and non-pregnant female patients not on ARVs and matched them with 
50 controls.30 Significantly more abnormalities were found amongst the HIV 
positive patients, with 30% displaying signs of systolic dysfunction  (reduced 
LV FS and EF) vs. 8% in controls and diastolic dysfunction (impaired E/A 
ratios or IVRT) in 32% vs. 8%. Again, pericardial effusions were appreciably 
higher in the HIV group with nearly half being affected with effusions of 
varying size, with none appearing in the control population. Only one patient 
with a pericardial effusion was symptomatic. 
 
	 27	
In the South African context, the Heart of Soweto Study prospectively studied 
all patients presenting to the cardiology unit at Chris Hani Baragwanath 
Hospital.31 Of 5328 cases of de novo heart disease, 9.7% were HIV positive. The 
most common diagnosis in these 518 patients was dilated cardiomyopathy 
(38% - LVEF <45% and LVEDD>55mm), with pericarditis/pericardial 
effusion (effusion > 0.5cm) being diagnosed in 25% of patients. HIV-
associated pulmonary artery hypertension was found in 8.1% and coronary 
artery disease in only 2.4%. 
 
Other cardiac manifestations of HIV 
Pericardial Effusions 
Pericardial effusions are the most common cardiac manifestation of HIV, with 
a prevalence of 20% and an incidence of 11% per year in the pre-HAART 
era.32 It is an independent predictor of mortality and does not necessarily 
correlate with CD4+ count. However, as HAART has become standard 
treatment, some studies have shown a decline in the prevalence of HIV-
associated pericardial effusion.33 As cytokine expression is enhanced in later 
stages of HIV, capillary leak increases resulting in serous fluid formation in 
the pleural and peritoneal surfaces. However, it is important to exclude other 
causes of a pericardial effusion, especially in areas where Mycobacterium 
Tuberculosis (TB) is endemic. GeneXpert studies may assist with in diagnosis.34 
In certain areas of Africa, TB is the causative organism in up to 86% of 
pericardial effusion in HIV positive patients.35 Other organisms that can cause 





Pulmonary Arterial Hypertension 
 
Patients with HIV are at increased risk for developing Pulmonary Artery 
Hypertension (PAH), probably due to a variety of viral factors that result in 
extensive remodeling of pulmonary vessels.36 HIV has also been identified in 
alveolar macrophages on histology. These macrophages release TNF-alpha, 
oxide anions, and proteolytic enzymes in response to infection.37 Pneumocystis 
pneumonia has also been implicated in the development of PAH, even after 
the disease has been fully treated. Signs and symptoms reflect the degree of 
disease and standard echocardiographic measures are used for diagnosis. It is 





An assortment of vasculitidies, including polyarteritis nodosa, has been 
associated with HIV infection, with an incidence of less than 1%. Large vessel 
vasculopathies including abdominal aortic aneurysms have been recognised 
in young African patients who have no other cause of vasculitis (e.g. syphilis) 
and present with slow-growing masses that may or may not be tender.38 
 
Endocarditis 
Infective endocarditis is common in HIV, and the prevalence varies from 6.4% 
to 34%.39 Although presentation is similar to HIV-negative patients, 
complication and mortality rates are higher in patients with advanced HIV. 
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Organisms include Staphylococcus aureus (75% of patients), Streptococcus 
pneumoniae, Haemophilus influenzae, and Candida Albicans. 
 
Coronary artery disease (CAD) and metabolic syndrome 
 
Initial reports have associated HIV with CAD since 1998, with accelerated 
atherosclerosis histologically distinct to HIV. Increase inflammatory markers 
may play a role and HIV-1 genomes have been found in coronary arteries of 
HIV positive patients dying of coronary arteritis and acute myocardial 
infarction.12 Protease inhibitors are known to cause dyslipidaemia and are 
strongly associated an increased risk of myocardial infarction.25 In Africa, 
CAD is relatively uncommon, but as socioeconomic changes occur, Western 
lifestyles and diet may have an impact on the burden of disease.31,38 
 
HIV and the anaesthetist 
 
In South Africa, HIV is a common co-morbidity in those patients presenting 
for surgery. As pericardial effusions, myocarditis, reduced ejection fraction 
systolic dysfunction and impaired diastolic function are common 
cardiovascular manifestations of HIV, anaesthetists should have a high index 
of suspicion for these abnormalities, in both the pregnant and non-pregnant 
population. Patients with a CD4+ of less than 100 and not on HAART are 
particularly at risk of HIV-associated cardiomyopathy, so an ECG, chest x-ray 






Peripartum cardiomyopathy (PPCM) occurs rarely but is a serious 
complication of pregnancy and can only be diagnosed in the absence of 
factors known to cause cardiomyopathy. It is characterized by new onset left 
ventricular failure between the last month of pregnancy and the first five 
months following delivery.40 PPCM affects between 1:300 and 1:3000 
pregnancies, depending on geographical areas. In South Africa, the incidence 
appears to be 1:1000.41  
 
A 2009 review of the aetiology and risk factors for PPCM describes multiple 
conflicting causes including the pathogenetic role of viral myocarditis, 
abnormal immune response to pregnancy, abnormal response to the 
haemodynamic stress of pregnancy, accelerated myocyte apoptosis, cytokine-
induced inflammation, malnutrition, genetic factors, excessive prolactin 
production, abnormal hormonal function, selenium deficiency, increased 
adrenergic tone and myocardial ischaemia.42 Important factors identified 
include vascular endothelial growth factor (VEGF), cathepsin D-cleaved 
16kDA prolactin43 and soluble fms-like tyrosine kinase-1 (sFlt-1) which 
disable proteins that promote new blood vessel development.44   
 
Other risk factors include advanced maternal age, high parity, high gravidity, 
prolonged lactation, twin pregnancy, the use of tocolytic therapy, African 
descent, non-Caucasian ethnicity and poverty. Other environmental factors 
may be at fault. In a high incidence area (one in a hundred live births) in 
Nigeria, young Hauta mothers lie on hot mud beds for up to forty days post-
partum and are made to ingest large amounts of ‘Kanwa’ salt from nearby 
Lake Chad. This results in significant hypervolemia and fluid overload.45 
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HIV and PPCM 
Theories regarding the aetiology of PPCM are widely divergent.42 Viral 
infiltration has been found in a significant portion of myocardial biopsies in 
patients with PPCM, and given that HIV itself may invade the myocardium, 
the HIV positive pregnant women may be predisposed to develop a dilated 
cardiomyopathy.  
 
A recent study by Sliwa et al did not show any worse outcomes in patients 
with PPCM infected with HIV as compared to a cohort without HIV.46 Eighty 
consecutive PPCM patients were recruited at South African hospitals and 
followed up over 24 months. As expected, due to the high HIV prevalence in 
South Africa, a third (34%) of patients were HIV positive. There was no 
difference in demographics, body habitus and blood pressure between the 
HIV positive and negative groups and no difference was found between 
baseline echocardiographic measurements (both groups LV ejection fraction 
30%). Even when compared at six-, twelve and 24-month intervals, there were 
no differences between the echocardiographic findings of the two groups. 
26% of the HIV group had a CD4 less than 200/mm3 (World Health 
Organisation stage 4) but only two were initiated on ARVs. Despite this, over 
the study period, there was no significant difference in mortality between the 
two groups.  
The only significant differences between the two groups were the lower 
hemoglobin levels (HIV+: 10.5 ± 2.1 g/dl vs. HIV-: 11.9 ± 1.7 g/dl) and a 
faster heart rate (110 ± 16 bpm vs. 97 ± 18 bpm). Pro-inflammatory cytokines, 
like TNFα, were equally elevated in both groups. These cytokines, in high 




HIV, pregnancy and cardiac dysfunction 
 
There is very little data on what cardiac changes occur, if any, in HIV positive 
pregnant women. Anecdotes and case reports form the bulk of our 
knowledge. Mandal and Dattaray describe a case in which an HIV positive 
mother presented with signs of congestive cardiac failure for first time late in 
the third trimester.47 Echocardiography showed a dilated cardiomyopathy in 
the absence of any other causes, with an ejection fraction (EF) of 35%, 
confirming the diagnosis of PPCM. Despite a reasonable CD4 count of 250, 
successful delivery of the fetus via caesarean section (CS) and appropriate 
anti-failure treatment, the patient succumbed to sustained ventricular 
tachycardia on the second day post-operatively. This well describes the 
increased risk during peri-partum care of patients with both diseases.  
 
Longenecker and colleagues examined 41 HIV infected and 41 HIV negative 
pregnant women in Uganda.48 Their study recruited HIV positive women at 
an average of 36 weeks gestation, at least 24 of whom were on ARVs, 
according to postnatal records. All patients were asymptomatic and 
underwent a standardized transthoracic echocardiogram according to 
American Society of Echocardiography guidelines. No echocardiographic 
evidence of peripartum cardiomyopathy or pulmonary hypertension was 
found – the seven measurements being left ventricular (LV) ejection fraction, 
LV end-diastolic volume index, LV mass index, left atrial (LA) volume index, 
mitral E/E’ ratio, RV systolic pressure and cardiac output. The study was 
hampered by the lack of CD4 count, viral load, and that patients were not at 





Given the cardiovascular changes of pregnancy and the known potential for 
the development of systolic and diastolic dysfunction in HIV positive 
patients, it is not unreasonable to suppose that the heart of an HIV-infected 
patient may respond differently to the demands of pregnancy as compared to 
an HIV negative patient. As anaesthetists involved in the safe delivery of 
many of these patients, it is imperative that we know, firstly, if HIV causes 
cardiovascular changes in pregnancy, secondly, to what extent these changes 
occur and thirdly, how these changes effect our management of HIV positive 
pregnant patients. Lastly, we need to know whether any changes that occur 
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Introduction: In South Africa, up to 30% of pregnant women are human 
immunodeficiency virus (HIV) positive and morbidity and mortality is high 
in this group. HIV positive men and women may have multiple 
cardiovascular comorbidities, which include systolic dysfunction that may 
progress to heart failure secondary to dilated cardiomyopathy. However the 
concurrent effect of pregnancy and HIV infection on haemodynamics has not 
been extensively researched. The aims of this study were to quantify 
haemodynamics using transthoracic echocardiography (TTE) in term 
pregnant women with HIV on Anti-Retroviral (ARV) treatment and compare 
the data with term healthy women in the same population.   
Method: After ethics approval and written consent, 30 consecutive term HIV 
positive women and 40 healthy term pregnant women were recruited. HIV 
positive women had a CD4 count greater than 200 and were either on Highly 
Active Anti-Retroviral Therapy (HAART) or single drug management.  
Results: Haemodynamic assessment was possible in all patients and women 
in the two groups were similar in age, and body mass index. Mean CD4 count 
was 452 ± 187.8 and duration of therapy was 15.9 ± 22.4 months. Compared 
with healthy pregnant women, women with HIV have systolic changes 
exhibited by reductions in LV septal and RV systolic myocardial velocities as 
well as increased LV ED areas and diastolic changes of increased RV IV 
relaxation and reduced RV e′ diastolic myocardial velocities. These changes 
occur in the presence of a reduced LV mass. Pericardial effusions occur more 
frequently and are of a larger size in women with HIV.  
These findings suggest subclinical impairment of systolic function in the LV 
as well as subclinical impairment of both systolic and diastolic function in the 
RV.   
Discussion:  
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Transthoracic echocardiography can quantify cardiac function in healthy 
pregnant women and in pregnant women with HIV and is acceptable to the 
patients. HIV positive pregnant women at term on anti-retroviral therapy 
have hearts that have subtle systolic dysfunction in the presence of decreased 
LV mass and increased end-diastolic areas. This may represent a failure to 
compensate for the increased haemodynamic demands of pregnancy and may 



















South Africa has experienced an incredibly rapid rise in HIV infection, where 
prevalence in adults has increased from about 1% in 1990 to about 25% in in 
2000.1 Despite the rollout by government of ARVs in 2005 and an overall rate 
now reduced to 17.9%, pregnant women remain disproportionately affected, 
with a prevalence up to 30% in 2010.2 Mortality and morbidity is high in this 
group, as demonstrated by maternal deaths in South Africa due to non-
pregnancy related infections representing 26% of all maternal deaths, of 
whom 90% were HIV positive.3  
 
HIV positive men and women may have multiple cardiovascular 
comorbidities, which include systolic dysfunction that may progress to heart 
failure due to dilated cardiomyopathy. Research in Rwanda has shown that 
HIV-associated dilated cardiomyopathy may occur in up to 17% of untreated 
HIV positive patients.4 In another prospective cohort trial, the incidence of 
systolic dysfunction was up to 34% and diastolic dysfunction of 48% in 
asymptomatic HIV positive patients on HAART.5 A recent limited study in 
Uganda suggests that HIV infection in pregnant patients on HAART is not 
necessarily a risk factor for the echocardiographic signs of cardiomyopathy or 
pulmonary hypertension.6   
 
However the effect of pregnancy and HIV infection on haemodynamics has 
not been extensively researched. Increasing dyspnea and haemodynamic 
changes associated with aortocaval compression caused by the normal 
physiological changes of pregnancy make the identification of cardiac disease 
problematic.  Recent developments in transthoracic echocardiography (TTE) 
have led to an improved understanding of cardiac physiology and 
pathophysiology of pregnancy.7 TTE not only enables better definition of 
cardiac dysfunction, but also contributes to point of care management in 
pregnancy.8 TTE has been shown to be acceptable and applicable in pregnant 
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women with no known side effects. TTE could help identify cardiac 




Our aims in this study were to recruit a group of otherwise healthy HIV 
positive pregnant women at term and compare cardiac structure and function 
using transthoracic echocardiography with a matched cohort of healthy 
pregnant patients. Transthoracic echocardiography is validated in pregnancy 
and is a well accepted and minimally invasive method of determining cardiac 
structure and function.9-11 
 
Methods 
This multicentre, prospective observational study was performed in 
collaboration with the Royal Women’s Hospital, Parkville and the University 
of Melbourne, Australia and Groote Schuur Hospital and Mowbray Maternity 
Hospital and The University of Cape Town, South Africa. This study formed 
part of the larger “Transthoracic echocardiography in pregnant women 
study”, approved by the Human Research Ethics Committee University of 
Cape Town 442/2013, UTN U1111-1147-2431, and registered with the 
Australian Clinical Trial Registry: ACTRN12613000992707. After written 
informed consent, we recruited a convenience sample of 30 term HIV women 
and 40 healthy term women (based on previous work which required 40 
healthy women for comparison haemodynamic data) from outpatient clinics 
from the two hospitals in South Africa.  
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Term HIV (CD4 count was greater than 200/mm3 and if they were on ARVs – 
either HAART or single drug therapy (zidovudine: AZT) and healthy women 
older than 18 years, were recruited electively at term (≥ 370 weeks gestation).  
 
Exclusion criteria included inability to consent, refusal, pre-existing or 
gestational diabetes, known cardiac or hypertensive disease, multiple 
pregnancy, a known uterine abnormality or abnormal placentation or any 
woman in labour.  
 
All ultrasound studies were performed by one of two trained 
echocardiography investigators (ATD, LN) using a Vivid Q or Vivid S6 with 
7.5 MHz transducer (GE VINGMED ULTRASOUND A/S N-3191 Horten, 
Norway) using 2-dimensional, M-mode, colour-flow, continuous, pulsed 
wave and tissue Doppler imaging according to American Society of 
Echocardiography guidelines and following the methodology previously 
published.12,13  
 
Transthoracic echocardiography occurred in the left lateral position after five 
minutes rest. A three lead electrocardiograph was attached. A mercury 
sphygmomanometer was placed on the left arm and baseline systolic and 
diastolic blood pressures were obtained, recording the diastolic value as 
Korotkoff V according to the American Heart Association guidelines. The 
measurement was made to the closest two mmHg. The mean arterial pressure 
was calculated.  
 
All echocardiography measurements were performed and analysed off-line. 
Each measurement was the average of three consecutive beats. Standard 
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views were obtained, including apical 2-, 4- and 5-chamber (A2C, A4C, A5C), 
and parasternal long and short axis (PLAX and PSAX) views. The exam 
included 2-dimensional imaging and continuous, pulse wave, colour flow and 
tissue Doppler. The stored images were reviewed and measured 
independently in random order by two investigators (AD/JC).  
 
Haemodynamic measurements were performed according to standard 
recommendations. Stroke volume was calculated after calculating the product 
of the left ventricular outflow tract (LVOT) diameter (cross sectional area) 
obtained from the PLAX view, and the Doppler derived velocity time integral 
of the left ventricular outflow tract (LVOT VTI), obtained from the A4C. This 
in turn multiplied by the heart rate gives cardiac output.  
 
Fractional shortening was measured using the M-mode recording at the tips 
of the mitral valve in the PLAX view. Fractional area change was measured 
during systole and diastole from the parasternal short axis image at the mid-
papillary level. Systemic vascular resistance was calculated from mean 
arterial pressure and cardiac output. Diastolic function was measured using 
mitral valve inflow velocities E and A (cm.s-1), mitral valve deceleration time 
(ms), mitral valve A wave duration (ms), isovolumetric relaxation time (ms) 
and left atrial diameter (cm). Myocardial Tissue Doppler recorded the 
myocardial interventricular septum diastolic velocities of e´ and a´ and the 
systolic velocity of s′. Insonation angles were between 0-5 degrees. The left 
ventricular mass was calculated using measurements obtained from the 
PLAX M-mode image of the left ventricle during diastole. The Tei index, the 
measurement of overall myocardial performance was measured using tissue 
Doppler time intervals. 
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Haemodynamic data are presented as mean (standard deviation [SD]) or 
number (proportion) of women. Where appropriate, data were compared 
using unpaired two-tailed t-tests with Welsh’s correction, and proportions 
compared using Fisher’s exact test. Interobserver and intraobserver variability 
was determined using Bland Altman methodology and expressed as bias 
(mean difference) and limits of agreement (2 × SD mean difference). A second 
observer (JMC) independently measured the LVOT diameter and LVOT VTI 
to enable interobserver variability to be calculated and the single observer 
(AD) performed one repeated measurement of the LVOT diameter and LVOT 
VTI four months apart to enable intraobserver variability to be calculated. P 




From August 2013 through December 2013, we recruited 83 women (Figure 
1). Six were excluded from the HIV group and seven from the healthy term 
group. There were no complications related to the study and no maternal 
deaths. No woman refused consent.  
 
The demographics of the HIV positive and healthy term patients are shown in 
Table 1. Anaemia, defined as haemoglobin concentration of <11.0 g.dl-1, was 
common in both groups, with up to a third in the healthy group and 17% in 
the HIV positive group. Obesity, defined as a body mass index of ≥ 30 kg.m-2, 
was present in 59% of the total cohort, with a mean of 32 in each group. 
 
The 30 term HIV and 40 healthy pregnant women were well matched for all 
characteristics except for smoking status. In the term HIV group, CD4 counts 
were 452 ± 187.8 cells/mm3 and the duration of treatment was 15.9 ± 22.4 
months (mean ± SD).   
 
Haemodynamics and left ventricular systolic data for the two groups of 
patients are shown in Table 2. HIV patients had significantly reduced cardiac 
indices and cardiac work indices, reduced septal s′ tissue Doppler velocities 
and increased left ventricular end-diastolic and end-systolic areas compared 
with gestationally matched healthy pregnant women. Corrected flow time 
was also significantly decreased. Three (10%) of HIV positive patients had left 
ventricular end diastolic diameters (LVEDD) greater than 5.3 cm. 
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Ten per cent of asymptomatic healthy term pregnant women demonstrated 
reductions in fractional shortening and one healthy patient had a dilated 
ventricle with a left ventricular end diastolic diameter of > 5.3 cm. 
 
Table 3 shows left ventricular diastolic and structural data for the two groups 
of patients.  Although there was no significant LV diastolic differences 
between the two groups, approximately 40% of healthy pregnant patients and 
patients with HIV had mitral value E/septal e′ ratios greater than eight, with 
two women in each group having mitral valve E/A ratios less than one. Other 
structural changes seen in the HIV group included a decreased LV mass 
(mean of 140g vs. 170g) and a decreased interventricular septal and LV 
posterior wall thickness. Pericardial effusions, although present about half of 
healthy women, were more common in patients with HIV (83% vs. 53%) and 
were also of larger size (mean 0.52 cm vs. 0.3 cm) than in healthy pregnant 
women. 
 
Right ventricular functional data are shown in table 4. Biphasic s′ waves were 
common in all groups. Patients with HIV had reductions in right ventricular 
s′ velocities, reductions in right ventricular e′ velocities and increases in the 
right ventricular isovolumetric relaxation time but with similar tricuspid 
annular plane systolic excursion (TAPSE) values compared with healthy 
pregnant women.  Right ventricular myocardial performance index (i.e. Tei 
index) was also increased. 
 
Interobserver variability, using Bland-Altman methodology, for the LVOT 
diameter and LVOT VTI was determined for the total group. The mean ± SD 
differences for the LVOT diameter and LVOT VTI between two observers 
ATD and JMC were 0.27 ± 1.1 mm and -0.71 ± 1.4 cm.s-1. For the LVOT 
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diameter this equates to 95% of the interobserver measurements being within 
2.2 mm (11 %) of the mean LVOT measurement for the 2 observers of 19.9 
mm. For the LVOT VTI this equates to 95% of the interobserver 
measurements being within 2.7 cm.s-1 (12 %) of the mean value for the two 
observers of 21.5 cm.s-1.  
 
Intraobserver variability, calculated using Bland-Altman methodology, for 
the LVOT diameter and LVOT VTI for the group, determined the mean ± SD 
differences for the LVOT diameter and LVOT VTI between two observations 
for the single observer AD to be 0.0 ± 0.2 mm and 0.05 ± 0.6 cm.s-1. For the 
LVOT diameter this equates to 95% of the intraobserver measurements being 
within 0.4 mm (2 %) of the mean LVOT measurement for the two 
observations of 19.9 mm. For the LVOT VTI this equates to 95% of the 
intraobserver measurements being within 1.1 cm.s-1 (5 %) of the mean value 




This study determined important haemodynamic and cardiac structural 
characteristics of HIV positive term pregnant women and healthy term 
women in the context of a high maternal mortality rate. In HIV positive term 
women, our data showed decreased systolic function in the left ventricle with 
significantly decreased cardiac index and decreased cardiac work index. 
Other findings consistent with this was a decreased LV septal s’. Diastolic 
changes in the LV included decreased lateral and septal a’ velocities. In the 
right ventricle, both the isovolumetric relaxation time and isovolumetric 
contraction time were increased, as well as decreased s’ and e’ velocities, 
demonstrating subclinical systolic and diastolic dysfunction. Other key 
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findings in the HIV group include a decreased LV mass (140 g vs. 170 g), 
increased LV end-diastolic and end-systolic areas (17.2 cm-2 vs. 15.1 cm-2; 7.6 
cm-2 vs. 6.3 cm-2) and increased number and size of pericardial effusions. 
Anaemia was a common co-existing problem. Not only did 17% of the HIV 
group have a haemoglobin less than 11g.dl-1, but so did 33% of the healthy 
women. This is however much lower than in a recent South African 
retrospective cohort study on anaemia in pregnancy in HIV positive women, 
with a prevalence of up to 64% with risk factors including a CD4 count less 
than 200 and increased gravidity.14 This discrepancy may be explained by our 
selection of patients with a CD4 count greater than 200. Anaemia in the 
healthy group may represent generalized socioeconomic conditions facing 
many South Africans, which in turn affect nutrition and other environmental 
factors. The potential affect of anaemia on cardiac output should be 
considered when interpreting findings.  
 
Regarding our haemodynamic findings, the presence of systolic and diastolic 
dysfunction is consistent with both European and African data in HIV 
positive non-pregnant populations.4,5,15,16 There is a relative lack of data on 
structural and functional changes in HIV positive pregnant patients. In our 
study, the HIV positive group had a significantly decreased cardiac index (2.8 
l.min-1 vs. 3.1 l.min-1. Longenecker et al studied HIV positive pregnant 
patients in Uganda, but certain important data are lacking.6 Of the 41 patients 
recruited in the HIV positive group, records for anti-retroviral treatment were 
only available for 24 patients, CD4 and viral load data are not available and 
the average gestational age at the time of the study was 36 weeks, compared 
to 39 and 40 weeks respectively in our HIV positive and healthy control 
groups. As antiretroviral therapy and the HI virus itself may all affect cardiac 
structures,17 it is difficult to make any concrete conclusions. Cardiac output in 
the Ugandan study was reported as not being significantly different (4.2 
l.min-1 vs. 4.3 l.min-1, p=0.84) but no correction for BMI was made. It is 
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possible that our findings of a dilated left ventricle (in both systole and 
diastole) and a decreased LV mass in conjunction with decreased left and 
right ventricular systolic myocardial velocities are representative of early 
echocardiographic signs of dilated cardiomyopathy. Reinsch et al, however, 
found that in a prospective study of 803 HIV-positive non-pregnant patients 
that the interventricular septum and posterior wall thickness were increased 
in 18.0% and 11.1%5. 
Pericardial effusions were common in both groups, with a prevalence of 83% 
in the HIV positive group. This is in keeping with other research which has 
shown that effusions are the most common manifestation of HIV associated 
cardiac changes.15,18 The overall prevalence is 20% in the non-pregnant 
population, which reaches 25% in the South African context.16 Pericardial 
effusions in HIV positive patients have been linked with an increased 
mortality rate, independent of CD4 count and are therefore an ominous 
sign.19 Figure 2 demonstrates the typical appearance of such a pericardial 
effusion. 
All patients studied were on ARVs, yet we know that ARVs can cause cardiac 
dysfunction.17 The World Health Organisation guidelines state that all 
pregnant patients should be initiated on HAART lifelong as first line therapy. 
These guidelines have been implemented in the Western Cape. The regimen 
in the Western Cape is for a fixed dose combination tablet (FDC) consisting of 
emtricitabine, tenofovir (both NRTIs) and efavirenz (NNRTI) once daily, 
commencing on the day of diagnosis. If HAART cannot be started promptly, 
patients are initiated on AZT until such time as they can be counseled and 
initiated. AZT is well known for its effects on myocyte mitochondria, which 
can result in dilated cardiomyopathy if given as a single drug and in high 
doses.20 The five women in our study on AZT were due to be initiated shortly, 
and therefore had limited exposure to the drug (less than six months). Nine 
women had been on ARVs for more than twelve months, and as such, were 
more likely to have myocardial changes due to their drug regimens. It is 
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unlikely however that the FDC combination would have significant cardiac 
effects.  
 
In South Africa, HIV is a common co-morbidity in those patients presenting 
for surgery. As pericardial effusions, myocarditis, reduced ejection fraction 
systolic dysfunction and impaired diastolic function are common 
cardiovascular manifestations of HIV, anaesthetists should have a high index 
of suspicion for these abnormalities, in both the pregnant and non-pregnant 
population. Patients with a CD4+ of less than 100 and not on HAART are 
particularly at risk of HIV-associated cardiomyopathy, so an ECG, chest x-ray 
and perioperative echocardiography may be warranted in such cases. The 
treating physician should therefore be cautious of diagnosing an HIV-positive 
patient presenting with signs and symptoms of a dilated cardiomyopathy 
with peripartum cardiomyopathy. 
 
This study has some limitations. All patients were recruited from a small 
geographical area and the study numbers were limited by the availability of 
appropriate staff to perform TTE. We did not record ethnicity as part of our 
demographic data, however data exists that demonstrate that black African 
women have a higher incidence of PPCM than their American counterparts, 
with some areas of Africa having an incidence as high as 1 in a 100 live births 
(compared to 1 in 4000 in Caucasian women).21 AZT is well known to have 
effects on the myocardium via mitochondrial toxicity, causing systolic 
dysfunction. Those patients on monotherapy may have been affected by this, 
although high doses and prolonged use are usually necessary for this to 
occur.17 Our findings were based on single echocardiographic examinations at 
term, not a set of serial examinations, and we have not performed follow up 






There is a paucity of longitudinal data on changes in cardiac structure and 
function in HIV positive patients through the whole of pregnancy, and 
further studies need to be conducted to find whether the changes found in 
this study return to baseline. It is yet unclear how environmental and dietary 
factors affect cardiac function in our population in South Africa, and how 
concomitant HIV infection is related to cardiac dysfunction in the Western 




This is the first study to show subclinical changes in cardiac structure and 
function in normal HIV positive women at term. In this population, anaemia 
and obesity are a problem. Term women with HIV were associated with 
reduced left and right ventricular systolic function shown by decreased left 
ventricular cardiac index, and decreased right ventricular s’ velocities. 
Structural changes were evidenced by pericardial effusions increased both in 
size and number as well as left ventricular dilatation and decreased left 
ventricular mass when compared with healthy pregnant women. Even in 
some healthy women, abnormal cardiac function was found to be present. We 
were able to establish echocardiographic reference ranges for healthy term 
women and term women with HIV. Point-of-care TTE was shown to be 
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Figure 2: Parasternal short axis view of an HIV-positive pregnant patient at 










Table 1 Demographic and obstetric data  

















HIV vs. Healthy 
Age (years) 27.0 (4.8) 27 (6.3) 0.928 
Gestation (weeks) 39 (1.6) 40 (1.8) 0.010 
Height (m) 161 (7.2) 160 (6.9) 0.262 
Weight (kg) 84 (18.1) 81 (17.4) 0.348 
Body mass index (kg.m-2) 32 (7.0) 32 (7.2) 0.646 
Nulliparous 6 (20) 14 (35)  0.193 
Haemoglobin (g.dl-1) 11.1 (1.4) 10.7 (1.42) 0.245 
Haemoglobin < 11.0 g.dl-1 5 (17) 13 (33)  0.172 
Current smoker 1 (3) 10 (25) 0.019 
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Table 2 Haemodynamic and left ventricular 
systolic data 







HIV vs.  
Healthy  
Systolic blood pressure (mmHg) 110 (15.4) 114 (20.2) 0.329 
Diastolic blood pressure (mmHg) 68 (13.2) 70 (14.0) 0.597 
Mean arterial pressure (mmHg) 82 (13.1) 84 (15.2) 0.454 
Cardiac index (ml.min-1.m-2) 2.8 (0.64) 3.1 (0.70) 0.029 
Systemic vascular resistance (dyne.s.cm-5) 1323 (343.9) 1237 (320.8) 0.290 
Cardiac output (ml.min-1) 5198 (1283.2) 5699 (1281.1) 0.091 
Stroke volume (ml) 64 (14.4) 65 (14.1) 0.625 
Heart rate (BPM) 83 (15.7) 88 (13.1) 0.162 
Left ventricular stroke work index (mmHg.ml.m-2) 2756 (661.6) 3016 (778.4) 0.137 
Left ventricular stroke work index (J.beat-1.m-2) 0.4 (0.09) 0.4 (0.10) 0.115 
Cardiac work index (mmHg.l.m-2) 226 (62.5) 265 (77.3) 0.025 
Fractional shortening (parasternal long axis) (%) 42 (6.3) 40 (8.8) 0.154 
Fractional shortening (parasternal long axis) < 28% 0 (0) 4 (10)  0.130 
LV end diastolic area (cm2) 17.2 (3.1) 15.1 (2.7) 0.004 
LV end systolic area (cm2) 7.6 (2.1) 6.3 (1.7) 0.005 
Fractional area change (%) 55.7 (8.1) 58.2 (9.9) 0.259 
Left ventricular end diastolic diameter (cm) 4.8  (0.49) 4.56 (0.44) 0.108 
Left ventricular end diastolic diameter > 5.3 cm 3 (10)  1 (3)  0.307 
Flow time (corrected) (ms) 358.7 (35.2) 395.4 (30.8) <0.001 
Left ventricular outflow tract maximal velocity(cm/s) 101.7 (15.6) 100.8 (18.5) 0.833 
J wave (LVOT) 22 (73)  39 (98)  <0.001 
Biphasic s´ wave (septal) 9 (31)  6 (15)  0.148 
Biphasic s´ wave (lateral) 23 (77)  25 (63)  0.299 
Septal isovolumetric contraction time (ms) 57.6 (9.9) 53.4 (10.7) 0.104 
Septal s´ duration (ms) 273.3 (33.8) 264.3(28.7) 0.260 
Septal s´ velocity (cm.s-1) 8.5 (1.5) 9.3 (1.7) 0.042 
Lateral s´ duration (ms) 275. 1 (36.7) 270.2 (36.0) 0.576 
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LV = left ventricle, RV = right ventricle, MV = mitral valve, BPM = beats per 
minute, LVOT = left ventricular outflow tract, Data are mean (SD), number of 
















Lateral s´ velocity (cm.s-1) 9.4 (2.31) 9.6 (1.69) 0.691 
Velocity circumferential fibre shortening - corrected  1.5 (0.23) 1.39 (0.42) 0.151 
Strain (Apical 4 Chamber) - - - 
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HIV vs.  
Healthy 
E velocity (cm.s-1) 88.5 (21.9) 91.9 (18.4) 0.500 
Deceleration time (ms) 158.2 (39.2) 145.3 (36.7) 0.167 
A velocity (cm.s-1) 56.4 (19.2) 63.4 (35.7) 0.295 
A duration (ms) 132.0 (30.8) 121.4 (20.6) 0.107 
Total mitral valve E&A wave duration 
(ms) 
375.1 (133.8) 354.3 (81.5) 0.454 
MV E/A 1.7 (0.65) 1.6 (0.50) 0.463 
MV E/A < 1 2 (7)  2 (5)  1.000 
MV beat fusion 17 (57)  21 (53)  0.811 
Left atrial diameter (cm) 3.6 (0.47) 3.6 (0.38) 0.759 
Septal e´ velocity (cm.s-1) 11.5 (2.4) 12.4 (2.5) 0.142 
Septal a´ velocity (cm.s-1) 7.4 (2.3) 8.5 (2.0) 0.041 
Septal e´/a´ 1.7 (0.7) 1.54 (0.49) 0.216 
Septal e´/a´ < 1 1 (3)  3 (8)  0.636 
Septal isovolumetric relaxation time 
(ms) 
62.5 (12.9) 63.9 (17.3) 0.699 
Septal isovolumetric contraction time 
(ms) 
57.6 (9.9) 53.4 (10.7) 0.104 
Lateral e´ velocity (cm.s-1) 13.4 (3.2) 14.4 (2.9) 0.175 
Lateral a´ velocity (cm.s-1) 6.6 (1.5) 8.1 (2.6) 0.003 
Lateral e´/a´ 2.1 (0.64) 1.94 (0.62) 0.220 
Lateral e´/a´ < 1  1 (4)  2 (5)  1.000 
Lateral isovolumetric relaxation time 
(ms) 
53.6 (13.1) 57.3 (13.4) 0.257 
Lateral isovolumetric contraction time 
(ms) 
61.3 (17.9) 59.5 (15.3) 0.660 
MV E/Septal e´ 7.7 (2.0) 7.73 (2.13) 0.893 
MV E/Septal e´ ≤ 8  17 (61)  24 (62)  1.000 
MV E/Septal e´ > 15 0 0 N/A 
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MV E/Lateral e´ 7.0 (2.3) 6.54 (1.54) 0.364 
MV E/Lateral e´ ≤ 8 20 (67) 32 (80)  0.272 
MV E/Lateral e´ >15 0 0 N/A 
(E/Septal e´)/LVEDD 1.5 (0.67) 1.72 (0.53) 0.194 
LVMPI 0.4 (0.08) 0.453 (0.117) 0.689 
Interventricular septal thickness (cm) 0.8 (0.17) 0.99 (0.17) <0.001 
Posterior wall thickness (cm) 1.0 (0.23) 1.11 (0.27) 0.021 
Left ventricular mass (g) 140 (38.8) 170(40.4) 0.003 
Pericardial effusion 25 (83)  21 (53)  0.011 
Size of effusion (cm) 0.52 (0.20) 0.3 (0.28) <0.001 
 
LV = left ventricle, RV = right ventricle, MV = mitral valve, EDD = end 
diastolic diameter, TDI = tissue Doppler indices, Data are mean ± SD, number 
of women (percentage), LVMPI = left ventricular myocardial performance 
index = Tei index (septal TDI) 
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Table 4 Right ventricular functional data 





HIV vs. Healthy 
TAPSE (cm) 2.54 (0.43) 2.64 (0.39) 0.327 
Biphasic s´ wave (Right ventricle) 23 (77)  25 (63)  0.299 
RV isovolumetric relaxation time 
(ms) 
44.1 (10.4) 37.5 (12.8) 0.008 
RV isovolumetric contraction time 
(ms) 
63.3 (8.0) 50.5 (15.5) <0.001 
RV s´ duration (ms) 257.1 (37.4) 264.3 (40.3) 0.759 
RV s´ velocity (cm.s-1) 14.7 (3.1) 17.0 (2.9) 0.001 
RV e´ velocity (cm.s-1) 16.3 (4.1) 18.7 (3.4) 0.013 
RV a´ velocity (cm.s-1) 14.9 (5.3) 15.2 (4.6) 0.806 
RV e´/a´ 1.17 (0.42) 1.32 (0.42) 0.226 
RV e´/a´ < 1 5 (18)  10 (26)  0.555 
RVMPI 0.42 (0.08) 0.35 (0.12) 0.002 
 
RV = right ventricle, TAPSE = Tricuspid annular plane excursion, RVMPI = 
right ventricular myocardial performance index, Data are mean (SD), number 









Appendix 1  
Consent form 
PARTICIPANT INFORMATION AND CONSENT FORM 
  
Site: Mowbray Maternity and Groote Schuur Hospitals, Cape Town, South 
Africa 
 
Full Project Title: Transthoracic echocardiography in pregnant women  
 
Principal Researcher: RA Dyer 
  
Associate Researchers: AT Dennis, M Gibbs, J Swanevelder 
 
1. Introduction 
You are invited to take part in this research project because you are receiving 
your care at either the Mowbray Maternity or the Groote Schuur Hospitals 
through which this research is being conducted.  
 
This is because you are either a woman who has developed preeclampsia 
(high blood pressure and protein in the urine) during your pregnancy, or you 
have HIV infection or you have developed a heart problem during your 
pregnancy, or you are a healthy pregnant woman.  
 
If you are a healthy pregnant women the results of your heart function test 
will be compared to sick pregnant women in order to help us understanding 
the differences between healthy women’s heart function and sick women’s 
heart function.   
 
The research project aims to determine heart function in women with 
preeclampsia or HIV before. This can assist with our understanding of these 
diseases. 
 
We also aim to examine the blood flow in your eye. This tells us about the 
blood flow in your brain. This may explain why some women get more sick 
than others, or may help predict which women will get more sick. 
 
This Participant Information and Consent Form tells you about the research 
project. It explains what is involved to help you decide if you want to take 
part. 
 
Please read this information carefully. Ask questions about anything that you 
don’t understand or want to know more about. Before deciding whether or 
not to take part, you might want to talk about it with a relative, friend or your 
local health worker. 
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Participation in this research is voluntary. If you don’t wish to take part, you 
don’t have to.  
 
If you decide you want to take part in the research project, you may be asked 
to sign the consent section. By signing it you are telling us that you: 
 
Understand what you have read;  
Consent to take part in the research project; 
Consent to be involved in the procedures described; 
Consent to the use of your personal and health information as described. 
 
You will be given a copy of this Participant Information and Consent Form to 
keep. 
 
2. What is the purpose of this research project? 
 
The aims of the project are to better understand heart function in women with 
preeclampsia, pregnant women with HIV, women who have heart problems 
in pregnancy and healthy pregnant women. This is important because there is 
very little information about how a woman’s heart responds to the diseases of 
preeclampsia and HIV. Understanding the response may help us treat the 
disease better. 
 
We also aim to better understand blood flow in the eyes in the same patients 
above. 
 
230 women will be taking part in the project. 
 
This project involves collaboration with researchers from The University of 
Melbourne and the Royal Women’s Hospital, Melbourne Australia.  
 
This research is supported by equipment supplied (GE Vivid Q transthoracic 
echocardiography machine) and software supplied by ProSolv software. 
 




Participation in this project will involve undergoing an ultrasound scan of 
your heart known as a transthoracic echocardiography (TTE) examination. 
The images of your heart will be recorded and stored for measurement after 
the scan is completed. This scan is exactly the same procedure as the 
ultrasound scan on your abdomen to examine your baby except that it is 
looking at your heart. It is a comfortable examination with no side effects. The 
TTE scan will take place with you lying comfortably on your left hand side on 
a bed, wearing your normal clothes or hospital gown. If you have 
preeclampsia after you have commenced medications another TTE scan may 
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be performed to examine the effect of the mediation on your heart. If you 
have a caesarean birth a TTE examination may be performed before, during 
and after the birth of your baby. This will not interfere with your birth 
experience or your ability to bond with your baby. The TTE images will not 
identify you. The TTE images will also be used for educational purposes to 
teach other health care professionals how to scan pregnant women’s hearts 
and perform measurements on the images.  
 
An ultrasound of your right or left eye will also be done. This is done by 
gently pressing a similar ultrasound probe to your closed eye and examining 
the blood flow in the main blood vessel that supplies the eye. The 




You will not be paid for your participation in this research. 
 
4. What are the possible benefits? 
 
We cannot guarantee or promise that you will receive any benefits from this 
project. 
There is the possibility that examination of your heart with the TTE may 
detect a previously undetected abnormality which could then be assessed and 
managed that would otherwise have gone undetected. It is possible that the 
findings of the TTE scan may assist with your management if the scan is 
performed when you are very sick. 
 
One aim of this study is to increase our knowledge of the effects on the heart 
of preeclampsia and HIV in pregnant women so this may have benefits for 
future women and their babies. 
 
5. What are the possible risks? 
 
There are no known risks of ultrasound to either you or your baby.  
 
6. Do I have to take part in this research project? 
 
Participation in any research project is voluntary. If you do not wish to take 
part, you do not have to. If you choose to not participate, this will not affect 
your treatment, care or relationship with this hospital. If you decide to take 
part and later change your mind, you are free to withdraw from the project at 
a later stage.  
 
7. How will I be informed of the final results of this research project? 
 
If you desire, you can be sent the results of this research in the form of a 
summary document or publication arising from the research. 
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8. What will happen to information about me? 
 
Any information obtained in connection with this research project that can 
identify you will remain confidential and will only be used for the purpose of 
this research project. It will only be disclosed with your permission, except as 
required by law. In any publication and/or presentation, information will be 
provided in such a way that you cannot be identified,   
 
9. Can I access research information kept about me? 
 
In accordance with relevant laws, you have the right to access the information 
collected and stored by the researchers about you.  Please contact one of the 
researchers named at the end of this document if you would like to access 
your information. 
 
In addition, in accordance with regulatory guidelines, the information 
collected in this research project will be kept for at least 5 years.  
 
10. Is this research project approved? 
 
The ethical aspects of this research project have been approved by the Human 




I have read, or have had this document read to me in a language that I 
understand, and I understand the purposes, procedures and risks of this 
research project as described within it. 
 
I have had an opportunity to ask questions and I am satisfied with the 
answers I have received. 
 
I freely agree to participate in this research project, as described.  
 













Declaration by researcher: I have given a verbal explanation of the research 
project, its procedures and risks and I believe that the participant has 








Signature        Date 
 
 
Note: All parties signing the consent section must date their own signature. 
 
 
Whom can I contact in connection with the study results? 
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importance	to	obstetric	anaesthetists/anesthesiologists	are	also	welcome.	The	journal	is	peer-
reviewed	by	international	experts.	Scholarship	is	stressed	to	include	the	focus	on	discovery,
application	of	knowledge	across	fields,	and	informing	the	medical	community.	Through	the
peer-review	process,	we	hope	to	attest	to	the	quality	of	scholarships	and	guide	the	Journal	to
extend	and	transform	knowledge	in	this	important	and	expanding	area.
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Types	of	article	
	Original	research	(both	clinical	and	laboratory),	case	series,	reports	and	correspondence	will	be	
considered.	To	be	accepted	for	publication,	individual	case	reports	need	to	have	important	and	
novel	learning	points;	a	simple	narrative	of	a	complex	or	challenging	patient(s)	is	insufficient.	
Case	series	dealing	with	important	areas	of	practice	with	a	thorough	review	of	relevant	literature	
will	be	considered.	The	journal	also	publishes	invited	review	articles	and	debates	on	topical	and	
controversial	subjects	in	the	area	of	obstetric	anaesthesia.	Reviews	are	usually	commissioned,	
although	authors	may	contact	the	Editor-in-Chief	if	they	wish	to	discuss	potential	topics.	
Contact	details	for	submission	
	Authors	may	send	queries	concerning	the	submission	process,	manuscript	status,	or	journal	
procedures	to	the	Editorial	Office	at:	
IJOA,	Editorial	Office,	ELSEVIER.	
E-mail:	ijoa@elsevier.com	
BEFORE	YOU	BEGIN	
Ethics	in	publishing	
	For	information	on	Ethics	in	publishing	and	Ethical	guidelines	for	journal	publication	see	
http://www.elsevier.com/publishingethics		and	http://www.elsevier.com/journal-
authors/ethics	.	
A	paper	that	contains	the	results	of	human	and/or	animal	studies	will	only	be	accepted	for	
publication	if	it	is	made	clear	that	a	high	standard	of	ethics	was	applied	in	carrying	out	the	
investigation.	All	clinical	investigators	must	follow	the	Ethical	Principles	for	Medical	Research	
Involving	Human	Subjects	outlined	in	the	Declaration	of	Helsinki		In	the	case	of	invasive	studies	
of	humans,	the	text	should	include	a	statement	that	the	research	protocol	was	approved	by	a	
local	institutional	review	board	or	ethics	committee	and	that	written	consent	was	obtained	from	
all	subjects.	For	case	reports	subjects	must	not	be	identifiable;	however,	the	patient's	written	
consent	to	publish	should	be	given	(see	Patient	Details).	Please	note	that	the	patient's	written	
consent	to	publication	of	the	case	MUST	be	given	and	included	with	the	submission.	Failure	to	
provide	written	consent	will	result	in	the	manuscript	being	rejected.	Where	there	are	difficulties	
obtaining	written	consent,	the	Editor-in-Chief	should	be	contacted	but	publication	will	only	be	
considered	in	exceptional	circumstances.	
Conflict	of	interest	
	All	authors	are	requested	to	disclose	any	actual	or	potential	conflict	of	interest	including	any	
financial,	personal	or	other	relationships	with	other	people	or	organizations	within	three	years	of	
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beginning	the	submitted	work	that	could	inappropriately	influence,	or	be	perceived	to	influence,	
their	work.	See	also	http://www.elsevier.com/conflictsofinterest	.	Further	information	and	an	
example	of	a	Conflict	of	Interest	form	can	be	found	at:	
http://help.elsevier.com/app/answers/detail/a_id/286/p/7923	.	
Submission	declaration	and	verification	
	Submission	of	an	article	implies	that	the	work	described	has	not	been	published	previously	
(except	in	the	form	of	an	abstract	or	as	part	of	a	published	lecture	or	academic	thesis	or	as	an	
electronic	preprint,	see	http://www.elsevier.com/postingpolicy	),	that	it	is	not	under	
consideration	for	publication	elsewhere,	that	its	publication	is	approved	by	all	authors	and	tacitly	
or	explicitly	by	the	responsible	authorities	where	the	work	was	carried	out,	and	that,	if	accepted,	
it	will	not	be	published	elsewhere	in	the	same	form,	in	English	or	in	any	other	language,	including	
electronically	without	the	written	consent	of	the	copyright-holder.	To	verify	originality,	your	
article	may	be	checked	by	the	originality	detection	service	CrossCheck	
http://www.elsevier.com/editors/plagdetect	.	
Changes	to	authorship	
	This	policy	concerns	the	addition,	deletion,	or	rearrangement	of	author	names	in	the	authorship	
of	accepted	manuscripts:	Before	the	accepted	manuscript	is	published	in	an	online	issue	:	
Requests	to	add	or	remove	an	author,	or	to	rearrange	the	author	names,	must	be	sent	to	the	
Journal	Manager	from	the	corresponding	author	of	the	accepted	manuscript	and	must	include:	
(a) the	reason	the	name	should	be	added	or	removed,	or	the	author	names	rearranged	and	(b)
written	confirmation	(e-mail,	fax,	letter)	from	all	authors	that	they	agree	with	the	addition,
removal	or	rearrangement.	In	the	case	of	addition	or	removal	of	authors,	this	includes
confirmation	from	the	author	being	added	or	removed.	Requests	that	are	not	sent	by
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the	corresponding	author	will	be	forwarded	by	the	Journal	Manager	to	the	corresponding	author,
who	must	follow	the	procedure	as	described	above.	Note	that:	(1)	Journal	Managers	will	inform
the	Journal	Editors	of	any	such	requests	and	(2)	publication	of	the	accepted	manuscript	in	an
online	issue	is	suspended	until	authorship	has	been	agreed.
After	the	accepted	manuscript	is	published	in	an	online	issue	:	Any	requests	to	add,	delete,	or
rearrange	author	names	in	an	article	published	in	an	online	issue	will	follow	the	same	policies	as
noted	above	and	result	in	a	corrigendum.
Reporting	clinical	trials
Researchers	are	recommended	to	pre-register	their	trials	on	a	public	registry	at	or	before	the
time	of	first	recruitment.	Several	web-based	public	registries	are	now	available	including
http:/http://www.clinicaltrials.gov	.	Nevertheless,	IJOA	does	not	currently	regard	pre-
registration	of	a	clinical	trial	as	a	compulsory	pre-requisite	to	submission	and	possible
publication,	and	does	not	favour	those	that	have	been	pre-registered	or	discriminate	against
those	that	have	not.
Copyright
Upon	acceptance	of	an	article,	authors	will	be	asked	to	complete	a	'Journal	Publishing
Agreement'	(for	more	information	on	this	and	copyright	see
http://www.elsevier.com/copyright).	Acceptance	of	the	agreement	will	ensure	the	widest
possible	dissemination	of	information.	An	e-mail	will	be	sent	to	the	corresponding	author
confirming	receipt	of	the	manuscript	together	with	a	'Journal	Publishing	Agreement'	form	or	a
link	to	the	online	version	of	this	agreement.	Subscribers	may	reproduce	tables	of	contents	or
prepare	lists	of	articles	including	abstracts	for	internal	circulation	within	their	institutions.
Permission	of	the	Publisher	is	required	for	resale	or	distribution	outside	the	institution	and	for
all	other	derivative	works,	including	compilations	and	translations	(please	consult
http://www.elsevier.com/permissions	).	If	excerpts	from	other	copyrighted	works	are
included,	the	author(s)	must	obtain	written	permission	from	the	copyright	owners	and	credit	the
source(s)	in	the	article.	Elsevier	has	preprinted	forms	for	use	by	authors	in	these	cases:	please
consult	http://www.elsevier.com/permissions	.
Retained	author	rights
As	an	author	you	(or	your	employer	or	institution)	retain	certain	rights;	for	details	you	are
referred	to:	http://www.elsevier.com/authorsrights	.
Role	of	the	funding	source
You	are	requested	to	identify	who	provided	financial	support	for	the	conduct	of	the	research
and/or	preparation	of	the	article	and	to	briefly	describe	the	role	of	the	sponsor(s),	if	any,	in	study
design;	in	the	collection,	analysis	and	interpretation	of	data;	in	the	writing	of	the	report;	and	in
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the	decision	to	submit	the	article	for	publication.	If	the	funding	source(s)	had	no	such	
involvement	then	this	should	be	stated.	Please	see	http://www.elsevier.com/funding	.	
Funding	body	agreements	and	policies	
	Elsevier	has	established	agreements	and	developed	policies	to	allow	authors	whose	articles	
appear	in	journals	published	by	Elsevier,	to	comply	with	potential	manuscript	archiving	
requirements	as	specified	as	conditions	of	their	grant	awards.	To	learn	more	about	existing	
agreements	and	policies	please	visit	http://www.elsevier.com/fundingbodies	.	
Open	access	
	This	journal	offers	authors	a	choice	in	publishing	their	research:	
Open	Access	
• Articles	are	freely	available	to	both	subscribers	and	the	wider	public	with	permitted	reuse
• An	Open	Access	publication	fee	is	payable	by	authors	or	their	research	funder
Subscription
• Articles	are	made	available	to	subscribers	as	well	as	developing	countries	and	patient	groups
through
our	access	programs	(http://www.elsevier.com/access	)
• No	Open	Access	publication	fee
All	articles	published	Open	Access	will	be	immediately	and	permanently	free	for	everyone	to
read	and	download.	Permitted	reuse	is	defined	by	your	choice	of	one	of	the	following	Creative
Commons	user	licenses:
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Creative	Commons	Attribution-NonCommercial-ShareAlike	(CC	BY-NC-SA)	:	for	noncommercial
purposes,	lets	others	distribute	and	copy	the	article,	to	create	extracts,	abstracts	and
other	revised	versions,	adaptations	or	derivative	works	of	or	from	an	article	(such	as	a
translation),	to	include	in	a	collective	work	(such	as	an	anthology),	to	text	and	data	mine	the
article,	as	long	as	they	credit	the	author(s),	do	not	represent	the	author	as	endorsing	their
adaptation	of	the	article,	do	not	modify	the	article	in	such	a	way	as	to	damage	the	author's	honor
or	reputation,	and	license	their	new	adaptations	or	creations	under	identical	terms	(CC	BY-NC-
SA).	Creative	Commons	Attribution-NonCommercial-NoDerivs	(CC	BY-NC-ND)	:	for
noncommercial	purposes,	lets	others	distribute	and	copy	the	article,	and	to	include	in	a	collective
work	(such	as	an	anthology),	as	long	as	they	credit	the	author(s)	and	provided	they	do	not	alter
or	modify	the	article.
Elsevier	has	established	agreements	with	funding	bodies,
http://www.elsevier.com/fundingbodies	.	This	ensures	authors	can	comply	with	funding	body
Open	Access	requirements,	including	specific	user	licenses,	such	as	CC	BY.	Some	authors	may	also
be	reimbursed	for	associated	publication	fees.	If	you	need	to	comply	with	your	funding	body
policy,	you	can	apply	for	the	CC	BY	license	after	your	manuscript	is	accepted	for	publication.
To	provide	Open	Access,	this	journal	has	a	publication	fee	which	needs	to	be	met	by	the	authors
or	their	research	funders	for	each	article	published	Open	Access.
Your	publication	choice	will	have	no	effect	on	the	peer	review	process	or	acceptance	of
submitted	articles.
The	publication	fee	for	this	journal	is	$2,500.00	,	excluding	taxes.	Learn	more	about	Elsevier's
pricing	policy:	http://www.elsevier.com/openaccesspricing
Language	(usage	and	editing	services)
Please	write	your	text	in	good	English	(American	or	British	usage	is	accepted,	but	not	a
mixture	of	these).	Authors	who	feel	their	English	language	manuscript	may	require	editing
to	eliminate	possible	grammatical	or	spelling	errors	and	to	conform	to	correct	scientific
English	may	wish	to	use	the	English	Language	Editing	service	available	from	Elsevier's
WebShop	(http://webshop.elsevier.com/languageediting/	)	or	visit	our	customer	support	site
(http://support.elsevier.com	)	for	more	information.
Informed	consent	and	patient	details
Studies	on	patients	or	volunteers	require	ethics	committee	approval	and	informed	consent,
which	should	be	documented	in	the	paper.	Appropriate	consents,	permissions	and	releases	must
be	obtained	where	an	author	wishes	to	include	case	details	or	other	personal	information	or
images	of	patients	and	any	other	individuals	in	an	Elsevier	publication.	Written	consents	must	be
retained	by	the	author	and	copies	of	the	consents	or	evidence	that	such	consents	have	been
obtained	must	be	provided	to	Elsevier	on	request.	For	more	information,	please	review	the
Elsevier	Policy	on	the	Use	of	Images	or	Personal	Information	of	Patients	or	other	Individuals	,
http://www.elsevier.com/patient-consent-policy	.	Unless	you	have	written	permission	from	the
74	
patient	(or,	where	applicable,	the	next	of	kin),	the	personal	details	of	any	patient	included	in	any	
part	of	the	article	and	in	any	supplementary	materials	(including	all	illustrations	and	videos)	
must	be	removed	before	submission.	You	can	find	an	example	of	a	generic	patient	consent	form	
here		which	you	may	use	if	you	do	not	have	one	available	from	you	own	research/clinic.	
Submission	
	Submission	to	this	journal	proceeds	totally	online	and	you	will	be	guided	stepwise	through	the	
creation	and	uploading	of	your	files.	The	system	automatically	converts	source	files	to	a	single	
PDF	file	of	the	article,	which	is	used	in	the	peer-review	process.	Please	note	that	even	though	
manuscript	source	files	are	converted	to	PDF	files	at	submission	for	the	review	process,	these	
source	files	are	needed	for	further	processing	after	acceptance.	All	correspondence,	including	
notification	of	the	Editor's	decision	and	requests	for	revision,	takes	place	by	e-mail	removing	the	
need	for	a	paper	trail.	Submission	of	an	article	implies	that	the	work	described	has	not	been	
published	previously	(except	as	an	abstract	or	part	of	a	published	lecture	or	academic	thesis),	
that	it	is	not	under	consideration	(in	whole	or	in	part)	for	publication	elsewhere,	that	its	
publication	is	approved	by	all	Authors	and	tacitly	or	explicitly	by	the	responsible	authorities	
where	the	work	was	carried	out,	and	that,	if	accepted,	it	will	not	be	published	elsewhere	in	the	
same	form,	in	English	or	in	any	other	language,	without	the	written	consent	from	the	
International	Journal	of	Obstetric	Anesthesia	,	the	copyright-holder.	
AUTHOR	INFORMATION	PACK	18	Dec	2013	www.elsevier.com/locate/ijoa	6	
Please	submit	your	article	via	http://ees.elsevier.com/ijoa	.	
PREPARATION	
Use	of	word	processing	software	
	It	is	important	that	the	file	be	saved	in	the	native	format	of	the	word	processor	used.	The	text	
should	be	in	single-column	format.	Keep	the	layout	of	the	text	as	simple	as	possible.	Most	
formatting	codes	will	be	removed	and	replaced	on	processing	the	article.	In	particular,	do	not	use	
the	word	processor's	options	to	justify	text	or	to	hyphenate	words.	However,	do	use	bold	face,	
italics,	subscripts,	superscripts	etc.	When	preparing	tables,	if	you	are	using	a	table	grid,	use	only	
one	grid	for	each	individual	table	and	not	a	grid	for	each	row.	If	no	grid	is	used,	use	tabs,	not	
spaces,	to	align	columns.	
The	electronic	text	should	be	prepared	in	a	way	very	similar	to	that	of	conventional	manuscripts	
(see	also	the	Guide	to	Publishing	with	Elsevier:	http://www.elsevier.com/guidepublication	).	
Note	that	source	files	of	figures,	tables	and	text	graphics	will	be	required	whether	or	not	you	
embed	your	figures	in	the	text.	See	also	the	section	on	Electronic	artwork.	
To	avoid	unnecessary	errors	you	are	strongly	advised	to	use	the	'spell-check'	and	'grammar-
check'	functions	of	your	word	processor.	
Manuscripts	should	have	1.5	line	spacing,	including	tables	and	references	and	lines	should	be	
numbered.	Pages	should	be	numbered	consecutively.	Authors	are	advised	to	study	recent	issues	
of	the	International	Journal	of	Obstetric	Anesthesia		to	assess	the	level	of	detail	required	for	
publication.	
For	guidance,	original	research	articles	should	not	exceed	3000	words,	case	reports	1500	words,	
reviews	5000	words,	editorials	1500	words	and	correspondence	750	words	(excluding	
references)	
Article	structure	
Abstract	.	This	should	consist	of	not	more	than	250	words	summarising	the	contents	of	the	article	
and	should	contain	no	references	or	abbreviations.	Where	appropriate	use	a	structured	abstract	
with	the	headings:	Background,	Methods,	Results,	Conclusions	-	followed	by	Key	Words.	
Headings	should	be	appropriate	to	the	nature	of	the	paper.	In	general	those	for	experimental	
papers	should	follow	the	usual	conventions.	Introduction,	Methods,	Results,	Discussion	etc.	do	
not	need	to	be	on	separate	sheets.	Other	papers	can	be	subdivided	as	the	author	desires;	the	use	
of	headings	enhances	readability.	Do	not	insert	compulsory	line	breaks	within	the	text.	When	
reporting	randomized	trials,	authors	are	advised	to	refer	to	http://www.consort-statement.org	.	
For	observational	studies	authors	should	refer	to	http://www.strobe-statement.org	.	
Essential	title	page	information	
• Title.		Concise	and	informative.	Titles	are	often	used	in	information-retrieval	systems.	Avoid
abbreviations	and	formulae	where	possible.
• Author	names	and	affiliations.		Where	the	family	name	may	be	ambiguous	(e.g.,	a	double	name),
please	indicate	this	clearly.	Present	the	authors'	affiliation	addresses	(where	the	actual	work	was
done)	below	the	names.	Indicate	all	affiliations	with	a	lower-case	superscript	letter	immediately
after	the	author's	name	and	in	front	of	the	appropriate	address.	Provide	the	full	postal	address	of
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each	affiliation,	including	the	country	name	and,	if	available,	the	e-mail	address	of	each	author.	
•	Corresponding	author.		Clearly	indicate	who	will	handle	correspondence	at	all	stages	of	
refereeing	and	publication,	also	post-publication.	Ensure	that	phone	numbers	(with	country	and	
area	code)	are	provided	in	addition	to	the	e-mail	address	and	the	complete	postal	address.	
Contact	details	must	be	kept	up	to	date	by	the	corresponding	author.	
	•	Present/permanent	address.		If	an	author	has	moved	since	the	work	described	in	the	article	
was	done,	or	was	visiting	at	the	time,	a	'Present	address'	(or	'Permanent	address')	may	be	
indicated	as	a	footnote	to	that	author's	name.	The	address	at	which	the	author	actually	did	the	
work	must	be	retained	as	the	main,	affiliation	address.	Superscript	Arabic	numerals	are	used	for	
such	footnotes.	
Abbreviations	
	Avoid	abbreviations	in	the	title	and	abstract.	All	unusual	abbreviations	should	be	fully	explained	
at	their	first	occurrence	in	the	text.	Avoid	numerous	invented	abbreviations.	All	measurements	
should	be	expressed	in	metric	units,	SI	units	being	preferred	except	in	the	case	of	fluid	pressures.	
For	more	detailed	recommendations,	authors	may	consult	the	Royal	Society	of	Medicine	
publication:	Units,	Symbols	and	Abbreviations:	A	Guide	for	Biological	and	Medical	Editors	and	
Authors.		Propriety	names	and	drugs,	instruments	etc.	if	essential,	should	start	with	initial	capital	
letters.	
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•	Make	sure	you	use	uniform	lettering	and	sizing	of	your	original	artwork.	
•	Embed	the	used	fonts	if	the	application	provides	that	option.	
•	Aim	to	use	the	following	fonts	in	your	illustrations:	Arial,	Courier,	Times	New	Roman,	Symbol,	
or	use	fonts	that	look	similar.	
•	Number	the	illustrations	according	to	their	sequence	in	the	text.	
•	Use	a	logical	naming	convention	for	your	artwork	files.	
•	Provide	captions	to	illustrations	separately.	
•	Size	the	illustrations	close	to	the	desired	dimensions	of	the	printed	version.	
•	Submit	each	illustration	as	a	separate	file.	
A	detailed	guide	on	electronic	artwork	is	available	on	our	website:	
http://www.elsevier.com/artworkinstructions	
You	are	urged	to	visit	this	site;	some	excerpts	from	the	detailed	information	are	given	here.	
Formats	
	If	your	electronic	artwork	is	created	in	a	Microsoft	Office	application	(Word,	PowerPoint,	Excel)	
then	please	supply	'as	is'	in	the	native	document	format.	
Regardless	of	the	application	used	other	than	Microsoft	Office,	when	your	electronic	artwork	is	
finalized,	please	'Save	as'	or	convert	the	images	to	one	of	the	following	formats	(note	the	
resolution	requirements	for	line	drawings,	halftones,	and	line/halftone	combinations	given	
below):	
EPS	(or	PDF):	Vector	drawings,	embed	all	used	fonts.	
TIFF	(or	JPEG):	Color	or	grayscale	photographs	(halftones),	keep	to	a	minimum	of	300	dpi.	
TIFF	(or	JPEG):	Bitmapped	(pure	black	&	white	pixels)	line	drawings,	keep	to	a	minimum	of	1000	
dpi.	
TIFF	(or	JPEG):	Combinations	bitmapped	line/half-tone	(color	or	grayscale),	keep	to	a	minimum	
of	500	dpi.	
Please	do	not:	
	•	Supply	files	that	are	optimized	for	screen	use	(e.g.,	GIF,	BMP,	PICT,	WPG);	these	typically	have	a	
low	number	of	pixels	and	limited	set	of	colors;	
•	Supply	files	that	are	too	low	in	resolution;	
•	Submit	graphics	that	are	disproportionately	large	for	the	content.	
Color	artwork	
	Please	make	sure	that	artwork	files	are	in	an	acceptable	format	(TIFF	(or	JPEG),	EPS	(or	PDF),	or	
MS	Office	files)	and	with	the	correct	resolution.	If,	together	with	your	accepted	article,	you	
submit	usable	color	figures	then	Elsevier	will	ensure,	at	no	additional	charge,	that	these	figures	
will	appear	in	color	on	the	Web	(e.g.,	ScienceDirect	and	other	sites)	regardless	of	whether	or	not	
these	illustrations	are	reproduced	in	color	in	the	printed	version.	For	color	reproduction	in	print,	
you	will	receive	information	regarding	the	costs	from	Elsevier	after	receipt	of	your	accepted	
article.		Please	indicate	your	preference	for	color:	in	print	or	on	the	Web	only.	For	further	
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information	on	the	preparation	of	electronic	artwork,	please	see	
http://www.elsevier.com/artworkinstructions	.	
Please	note:	Because	of	technical	complications	which	can	arise	by	converting	color	figures	to	
'gray	scale'	(for	the	printed	version	should	you	not	opt	for	color	in	print)	please	submit	in	
addition	usable	black	and	white	versions	of	all	the	color	illustrations.	
Figure	captions	
Ensure	that	each	illustration	has	a	caption.	Supply	captions	separately,	not	attached	to	the	figure.	
A	caption	should	comprise	a	brief	title	(not		on	the	figure	itself)	and	a	description	of	the	
illustration.	Keep	text	in	the	illustrations	themselves	to	a	minimum	but	explain	all	symbols	and	
abbreviations	used.	
Tables	
	Number	tables	in	the	order	in	which	they	are	cited	in	the	text.	Place	footnotes	to	tables	below	the	
table	body	and	indicate	them	with	superscript	lowercase	letters.	Avoid	vertical	rules.	Ensure	that	
the	data	presented	in	tables	are	not	duplicated	in	the	text.	
Citation	in	text	
Please	ensure	that	every	reference	cited	in	the	text	is	also	present	in	the	reference	list	(and	vice	
versa).	Any	references	cited	in	the	abstract	must	be	given	in	full.	Unpublished	results	and	
personal	communications	are	not	recommended	in	the	reference	list,	but	may	be	mentioned	in	
the	text.	If	these	references	are	included	in	the	reference	list	they	should	follow	the	standard	
reference	style	of	the	journal	and	should	include	a	substitution	of	the	publication	date	with	either	
'Unpublished	results'	or	
'Personal	communication'.	Citation	of	a	reference	as	'in	press'	implies	that	the	item	has	been	
accepted	for	publication.	
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Reference	style	
The	accuracy	of	references	is	the	responsibility	of	the	author.	References	should	be	entered	
consecutively	by	superscript	Arabic	numbers	in	the	text	after	punctuation	and	not	preceded	by	
spaces.	The	references	should	be	listed	in	numerical	order.	References	to	journals	should	include	
the	author's	name	and	initials	(list	all	authors	when	six	or	fewer;	when	seven	or	more,	list	only	
the	first	three	and	add	et	al.),	full	title	of	the	paper,	journal	title	abbreviated	using	Index	Medicus		
abbreviations,	year	of	publication,	volume	number,	first	and	last	page	numbers.	If	not	in	Index	
Medicus		journal	titles	should	be	given	in	full.	
For	example:	Scott	DB,	Tunstall	ME.	Serious	complications	associated	with	epidural/spinal	
blockade.	Int	J	Obstet	Anesth	1995;	4:	133-9.	
References	to	books	should	be	set	out	as	follows:	Eisenach	JC.	The	pain	of	childbirth	and	its	effect	
on	the	mother	and	fetus.	In:	Chestnut	DH,	ed.	Obstetric	Anesthesia	Principles	and	Practice.	3rd	
ed.	Philadelphia:	Elsevier	Mosby;	2004:3288-301.	
Citing	and	listing	of	Web	references	.	As	a	minimum,	the	title	of	the	website	or	document,	the	full	
uniform	resource	locator	(URL)	and	the	accessed	date	should	be	given.	Any	further	information,	
if	known	(DOI,	author	names,	reference	to	a	source	publication,	etc.),	should	also	be	given.	Web	
references	should	be	included	in	order	of	citation,	in	the	reference	list.	Electronic	material	from	
a	web	site	should	be	set	out	as	follows:	National	Institutes	of	Health.	NIH	guidelines	on	the	
inclusion	of	women	as	subjects	in	clinical	research.	Available	at:	
http://grants.nih.gov/grants/guide/not94-100.html	.	Accessed	September	30,	2009.	
Journal	abbreviations	source	
Journal	names	should	be	abbreviated	according	to	the	List	of	title	word	abbreviations:	
http://www.issn.org/2-22661-LTWA-online.php	.	
Supplementary	data	
Elsevier	accepts	electronic	supplementary	material	to	support	and	enhance	your	scientific	
research.	Supplementary	files	offer	the	author	additional	possibilities	to	publish	supporting	
applications,	high	resolution	images,	background	datasets,	sound	clips	and	more.	Supplementary	
files	supplied	will	be	published	online	alongside	the	electronic	version	of	your	article	in	Elsevier	
Web	products,	including	ScienceDirect:	http://www.sciencedirect.com	.	In	order	to	ensure	that	
your	submitted	material	is	directly	usable,	please	provide	the	data	in	one	of	our	recommended	
file	formats.	Authors	should	submit	the	material	in	electronic	format	together	with	the	article	
and	supply	a	concise	and	descriptive	caption	for	each	file.	For	more	detailed	instructions	please	
visit	our	artwork	instruction	pages	at	http://www.elsevier.com/artworkinstructions	.	
Submission	checklist	
The	following	list	will	be	useful	during	the	final	checking	of	an	article	prior	to	sending	it	to	the	
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journal	for	review.	Please	consult	this	Guide	for	Authors	for	further	details	of	any	item.	
Ensure	that	the	following	items	are	present:	
	One	author	has	been	designated	as	the	corresponding	author	with	contact	details:	
• E-mail	address
• Full	postal	address
• Phone	numbers
All	necessary	files	have	been	uploaded,	and	contain:
• Keywords
• All	figure	captions
• All	tables	(including	title,	description,	footnotes)
Further	considerations
• Manuscript	has	been	'spell-checked'	and	'grammar-checked'
• References	are	in	the	correct	format	for	this	journal
• All	references	mentioned	in	the	Reference	list	are	cited	in	the	text,	and	vice	versa
• Permission	has	been	obtained	for	use	of	copyrighted	material	from	other	sources	(including	the
Web)
• Color	figures	are	clearly	marked	as	being	intended	for	color	reproduction	on	the	Web	(free	of
charge)	and	in	print,	or	to	be	reproduced	in	color	on	the	Web	(free	of	charge)	and	in	black-and-
white	in	print
• If	only	color	on	the	Web	is	required,	black-and-white	versions	of	the	figures	are	also	supplied
for	printing	purposes
For	any	further	information	please	visit	our	customer	support	site	at	http://support.elsevier.com
.
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Use	of	the	Digital	Object	Identifier
The	Digital	Object	Identifier	(DOI)	may	be	used	to	cite	and	link	to	electronic	documents.	The	DOI
consists	of	a	unique	alpha-numeric	character	string	which	is	assigned	to	a	document	by	the
publisher	upon	the	initial	electronic	publication.	The	assigned	DOI	never	changes.	Therefore,	it	is
an	ideal	medium	for	citing	a	document,	particularly	'Articles	in	press'	because	they	have	not	yet
received	their	full	bibliographic	information.	Example	of	a	correctly	given	DOI	(in	URL	format;
here	an	article	in	the	journal	Physics	Letters	B	):
http://dx.doi.org/10.1016/j.physletb.2010.09.059
When	you	use	a	DOI	to	create	links	to	documents	on	the	web,	the	DOIs	are	guaranteed	never	to
change.
Proofs
One	set	of	page	proofs	(as	PDF	files)	will	be	sent	by	e-mail	to	the	corresponding	author	(if	we	do
not	have	an	e-mail	address	then	paper	proofs	will	be	sent	by	post)	or,	a	link	will	be	provided	in
the	e-mail	so	that	authors	can	download	the	files	themselves.	Elsevier	now	provides	authors	with
PDF	proofs	which	can	be	annotated;	for	this	you	will	need	to	download	Adobe	Reader	version	7
(or	higher)	available	free	from	http://get.adobe.com/reader	.	Instructions	on	how	to	annotate
PDF	files	will	accompany	the	proofs	(also	given	online).	The	exact	system	requirements	are	given
at	the	Adobe	site:	http://www.adobe.com/products/reader/tech-specs.html	.
If	you	do	not	wish	to	use	the	PDF	annotations	function,	you	may	list	the	corrections	(including
replies	to	the	Query	Form)	and	return	them	to	Elsevier	in	an	e-mail.	Please	list	your	corrections
quoting	line	number.	If,	for	any	reason,	this	is	not	possible,	then	mark	the	corrections	and	any
other	comments	(including	replies	to	the	Query	Form)	on	a	printout	of	your	proof	and	return	by
fax,	or	scan	the	pages	and	e-mail,	or	by	post.	Please	use	this	proof	only	for	checking	the
typesetting,	editing,	completeness	and	correctness	of	the	text,	tables	and	figures.	Significant
changes	to	the	article	as	accepted	for	publication	will	only	be	considered	at	this	stage	with
permission	from	the	Editor.	We	will	do	everything	possible	to	get	your	article	published	quickly
and	accurately	–	please	let	us	have	all	your	corrections	within	48	hours.	It	is	important	to	ensure
that	all	corrections	are	sent	back	to	us	in	one	communication:	please	check	carefully	before
replying,	as	inclusion	of	any	subsequent	corrections	cannot	be	guaranteed.	Proofreading	is	solely
your	responsibility.	Note	that	Elsevier	may	proceed	with	the	publication	of	your	article	if	no
response	is	received.
Offprints
The	corresponding	author,	at	no	cost,	will	be	provided	with	a	PDF	file	of	the	article	via	email
(the	PDF	file	is	a	watermarked	version	of	the	published	article	and	includes	a	cover	sheet
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with	the	journal	cover	image	and	a	disclaimer	outlining	the	terms	and	conditions	of	use).	For	
an	extra	charge,	paper	offprints	can	be	ordered	via	the	offprint	order	form	which	is	sent	once	
the	article	is	accepted	for	publication.	Both	corresponding	and	co-authors	may	order	offprints	
at	any	time	via	Elsevier's	WebShop	(http://webshop.elsevier.com/myarticleservices/offprints	).	
Authors	requiring	printed	copies	of	multiple	articles	may	use	Elsevier	WebShop's	
'Create	Your	Own	Book'	service	to	collate	multiple	articles	within	a	single	cover	
(http://webshop.elsevier.com/myarticleservices/offprints/myarticlesservices/booklets	).	
AUTHOR	INQUIRIES	
For	inquiries	relating	to	the	submission	of	articles	(including	electronic	submission)	please	visit	
this	journal's	homepage.	For	detailed	instructions	on	the	preparation	of	electronic	artwork,	
please	visit	http://www.elsevier.com/artworkinstructions	.	Contact	details	for	questions	arising	
after	acceptance	of	an	article,	especially	those	relating	to	proofs,	will	be	provided	by	the	
publisher.	
You	can	track	accepted	articles	at	http://www.elsevier.com/trackarticle	.	You	can	also	check	
our	Author	FAQs	at	http://www.elsevier.com/authorFAQ		and/or	contact	Customer	Support	via	
http://support.elsevier.com	.	
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